Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee weighs allowing investigational ibogaine studies as doctors and agencies flag ethical and legal risks
Summary
Sponsors proposed a narrow amendment to permit investigational prescribing of ibogaine for clinical trials; DHHS and clinical leaders said properly overseen IRB processes already exist and cautioned that legislation could create misleading safety signals for vulnerable patients and that Schedule I status complicates access.
The committee held a hearing on HB 17‑72 FNA, a measure addressing investigational use of ibogaine, a Schedule I psychoactive compound derived from a Central African shrub that proponents say may aid veterans and others with PTSD, TBI and substance use disorders.
Sponsor Representative Mike Moffett framed ibogaine as a promising treatment for veterans and noted early studies showing symptom reductions in small cohorts. He and other supporters described a multi‑state consortium model and planned amendments to limit use to investigational contexts and to create an administrative fund ($1…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
